Table 4.
Report on all papers about cabozantinib and stomatitis.
| Authors | Year | Neoplasia | nNumber of cases | Stomatitis total | Stomatitis grade 1 | Stomatitis grade 2 | Stomatitis grade 3 | Stomatitis grade 4 | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Neal et al. [61] | 2016 | Phase II trial for EGFR wild-type non-small-cell lung cancer A: erlotinib B: cabozantinib C: erlotinib + cabozantinib |
A: 40 B: 40 C: 39 |
A: 2 (5%) B: 17 (43%) C: 9 (24%) |
A: 2 (5%) B: 13 (33%) C: 8 (21%) |
A: 0 B: 4 (10%) C: 1 (3%) |
A: 0 B: 0 C: 0 |
|
|
| |||||||||
| 2 | Tolaney et al. [62] | 2017 | Phase II metastatic triple negative breast cancer A: oral dosing of cabozantinib at 60 mg daily over a 21-day cycle |
A: 35 | A: 13 (37%) | A: 11 | A: 2 | A: 0 | A: 0 |
|
| |||||||||
| Total | 114 | 39 (34.21%) | 34 (29.82%) | 5 (4.38%) | |||||